during the nine months ended September 30, 2024 costs from two vendors each represented 37 % and 17 % of total research and development expenses, respectively
Reviva Pharmaceuticals Holdings, Inc. Customers
No clients on recordNo downstream customers found in our database for Reviva Pharmaceuticals Holdings, Inc..
Reviva Pharmaceuticals Holdings, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RVPH-DEBT-12306
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
RVPH-DEBT-12305
Warrants outstanding: 19075842
90%
xbrl warrant detail from xbrl 2026-03-31.
RVPH-DEBT
Debt stack $231,274
90%
Market cache reports total debt of $231,274.
Reviva Pharmaceuticals Holdings, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Reviva Pharmaceuticals Holdings, Inc..
Reviva Pharmaceuticals Holdings, Inc. Ownership
Holder
Name
Confidence
Evidence
RVPH-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 5 tracked holders.
Reviva Pharmaceuticals Holdings, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
Reviva Pharmaceuticals Holdings, Inc. Supply Chain Intel